---
schema_version: "secwatch.filing_event.v1"
accession: "0000719135-24-000013"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:41:52.370373+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q4 revenue up 16% to $14.7M; net loss widens to $9.6M; FY2024 guidance implies potential revenue decline

## Summary
- Q4 2023 Advanced Energy revenue $12.1M (+15% YoY); net loss $9.6M ($0.28/shr) vs $6.0M ($0.17) a year ago.
- Full year 2023 total revenue $52.3M (+18%); net loss improved to $18.7M ($0.54/shr) from $23.2M ($0.67) in 2022.
- FY2024 guidance: revenue $49.7M-$52.9M (down 5% to up 1%); net loss $24.3M-$26.5M, wider than 2023's $18.7M loss.
- New $45M Perceptive credit facility closed Nov 2023; initial $37.5M funded, used to repay MidCap and $2.7M in fees.
- Appointed Matthew Hill as CFO effective Dec 4, 2023.

## SEC filing metadata
- accession: 0000719135-24-000013
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/0000719135-24-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/apyx-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000719135-24-000013
- JSON: https://secwatch.observer/filing/0000719135-24-000013.json
- Plain text: https://secwatch.observer/filing/0000719135-24-000013.txt

## Key facts
- Earnings Releases
  Apyx Medical Corp reported year ended December 31, 2023 results: revenue $52.3 million, net income Net loss attributable to stockholders of $18.7 million. Guidance initiated.
  - Period: year ended December 31, 2023
  - Revenue: $52.3 million
  - Net income: Net loss attributable to stockholders of $18.7 million
  - Guidance: initiated
  - Result: reported results
  source text: or 59%, year-over-year. • Adjusted EBITDA loss of $4.7 million, an increase of $0.6 million, or 14%, year-over-year. Full Year 2023 Financial Summary : • Total revenue of $52.3 million, an increase of 18% year-over-year. ◦ Advanced Energy revenue of $43.4 million, an increase of 18% year-over-year. ◦ OEM revenue of $9.0 million, an increase of 16%
  evidence_url: https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/0000719135-24-000013-index.htm
- Earnings Releases
  Apyx Medical Corp reported three months ended December 31, 2023 results: revenue $14.7 million, net income Net loss attributable to stockholders of $9.6 million.
  - Period: three months ended December 31, 2023
  - Revenue: $14.7 million
  - Net income: Net loss attributable to stockholders of $9.6 million
  - Result: reported results
  source text: full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024. Fourth Quarter 2023 Financial Summary : • Total revenue of $14.7 million, an increase of 16% year-over-year. ◦ Advanced Energy revenue of $12.1 million, an increase of 15% year-over-year. ◦ OEM revenue of $2.5 million, an increase of 22%
  evidence_url: https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/0000719135-24-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.